文献速递心脑血管急症

轻度降低射血分数心肌梗死后的β受体阻滞剂:随机对照试验个体患者数据荟萃分析

β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials.
PubMed 文献 · Lancet · 2025-08-30
一句话结论急性心梗伴LVEF轻度降低(40-49%)且无心力衰竭史或体征者,口服β受体阻滞剂与主要复合终点降低相关(HR 0.75)。

该个体患者数据荟萃分析纳入4项近期随机对照试验中的1885例急性心肌梗死伴LVEF轻度降低(40-49%)且无心力衰竭史或体征的患者,比较口服β受体阻滞剂(991例)与对照(894例)的长期效果。主要复合终点(全因死亡、新发心肌梗死或心力衰竭)在β受体阻滞剂组106例(32.6事件/1000患者年)vs 对照组129例(43.0事件/1000患者年),HR 0.75(95%CI 0.58-0.97),p=0.031,试验间无显著异质性(交互作用p=0.95)。结果表明β受体阻滞剂治疗与该人群主要复合终点降低相关,将既往在LVEF降低心梗患者中的已知获益扩展至LVEF轻度降低亚组。

要点

  • 急性心梗伴LVEF轻度降低(40-49%)且无心力衰竭史或体征者,口服β受体阻滞剂使主要复合终点从43.0降至32.6事件/1000患者年,HR 0.75(95%CI 0.58-0.97)。
  • 主要复合终点为全因死亡、新发心肌梗死或心力衰竭,β受体阻滞剂组106例 vs 对照组129例。
  • 4项试验间无显著异质性(试验×治疗交互作用p=0.95),入组国家间亦无显著异质性(交互作用p=0.98)。
  • 纳入标准为近期心梗(随机化在14天内)、LVEF轻度降低(40-49%)、无心力衰竭史或体征,试验测试口服β受体阻滞剂长期效果(中位随访>1年)。
  • 该分析纳入REBOOT(979例)、BETAMI(422例)、DANBLOCK(430例)和CAPITAL-RCT(54例)四项试验。

适用人群与场景

  • 急性心肌梗死伴LVEF轻度降低(40-49%)且无心力衰竭史或体征的患者,随机化在心肌梗死14天内。

处置流程与药物剂量

  • 口服β受体阻滞剂治疗,长期给药(中位随访>1年)。

研究设计与关键结果

  • 个体患者数据荟萃分析纳入4项随机对照试验共1885例患者:β受体阻滞剂组991例,对照组894例。
  • 主要复合终点(全因死亡、新发心肌梗死或心力衰竭)β受体阻滞剂组106例(32.6事件/1000患者年)vs 对照组129例(43.0事件/1000患者年),HR 0.75(95%CI 0.58-0.97),p=0.031。
  • 试验间无显著异质性(试验×治疗交互作用p=0.95),入组国家间亦无显著异质性(交互作用p=0.98)。
  • 所有终点均独立裁定;该荟萃分析在PROSPERO注册(CRD420251023480)。

证据类型、等级与局限

  • 证据类型:随机对照试验的个体患者数据荟萃分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在急性心肌梗死伴LVEF轻度降低且无心力衰竭史或临床体征的患者中,β受体阻滞剂治疗与全因死亡、新发心肌梗死或心力衰竭复合终点降低相关。
  • 作者认为,这些结果将β受体阻滞剂在LVEF降低心梗患者中的已知获益扩展至LVEF轻度降低亚组。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The effects of β-blocker therapy on clinical outcomes in patients with myocardial infarction and mildly reduced (40-49%) left ventricular ejection fraction (LVEF) are largely unknown. Four recently conducted randomised trials tested the efficacy of β blockers after a recent myocardial infarction in patients without reduced LVEF (LVEF ≥40%). However, none were individually powered to assess these effects in the subgroup of patients with mildly reduced LVEF. We aimed to assess the efficacy of β blockers in patients with myocardial infarction and mildly reduced LVEF during the index hospitalisation.

METHODS: We conducted an individual patient-level meta-analysis of patients with mildly reduced LVEF and no history or signs of heart failure from four recent clinical trials. These studies were included because they were randomised controlled trials testing long-term effects (median follow-up >1 year) of oral β-blocker therapy in patients who recently had a myocardial infarction (randomisation within 14 days) and had mildly reduced LVEF. No further studies were found in a systematic review (Jan 1, 2020 to June 26, 2025). A one-stage, fixed-effects, Cox proportional hazards regression model was used to assess the treatment effect of β blockers on the predefined primary composite endpoint of all-cause death, new myocardial infarction, or heart failure. All endpoints were independently adjudicated. This meta-analysis was registered with PROSPERO (CRD420251023480).

FINDINGS: 1885 patients with myocardial infarction and mildly reduced LVEF were included in the meta-analysis: 979 from the REBOOT trial, 422 from the BETAMI trial, 430 from the DANBLOCK trial, and 54 from the CAPITAL-RCT trial. Overall, 991 patients were assigned to β blockers and 894 to control (no β blockers). The primary composite endpoint occurred in 106 patients (32·6 events per 1000 patient-years) in the β-blocker group and 129 patients (43·0 per 1000 patient-years) in the no β-blocker group (hazard ratio 0·75 [95% CI 0·58-0·97]; p=0·031). No heterogeneity between the trials (trial-by-treatment pinteraction=0·95) or between countries of enrolment was observed (pinteraction=0·98).

INTERPRETATION: In patients with acute myocardial infarction with mildly reduced LVEF without history or clinical signs of heart failure, β-blocker therapy was associated with a reduction in the composite of all-cause death, new myocardial infarction, or heart failure. These results extend the known benefits of these agents in patients with myocardial infarction with reduced LVEF to the subgroup with mildly reduced LVEF.

FUNDING: Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Danish Heart Foundation, Novo Nordisk Foundation, South-Eastern Norway Regional Health Authority, and Research Council of Norway.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Rossello X, Prescott EIB, Kristensen AMD, et al. β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials. Lancet. 2025. PMID: 40897190. doi:10.1016/S0140-6736(25)01592-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。